Implanted patches of iPS cell-derived heart muscle integrated with heart tissue in a primate model of heart failure, and in patients being treated in a clinical trial, marks progress toward a potential option for patients with advanced heart failure.
The University of Texas MD Anderson Cancer Center has launched its Institute for Cell Therapy Discovery & Innovation, which seeks to build upon MD Anderson clinical and research expertise to advance impactful cell therapies.
Chimeric antigen receptor (CAR) T-cell therapies (CAR T) have proven effective in several hematological cancers and are advancing across the pipelines of other types of tumors with limited efficacy, such as in the more complex environment of solid tumors.
Kytopen Corp. has received a phase II Small Business Innovation Research (SBIR) grant of $1.6 million from the NIAID/NIH to support preclinical studies of its engineered natural killer (NK) cells. The funding will be used to conduct in vivo preclinical studies, which will be conducted by Charles River Laboratories
Abata Therapeutics Inc. announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis (MS). Abata obtained FDA clearance for a first-in-human study of ABA-101 in patients with MS in July.
Many patients with peripheral nerve diseases do not have a sufficient regenerative response because of genetic inheritance, infections or chronic disease, leading them to lifelong pain and disability.
Researchers from Fate Therapeutics Inc. presented preclinical data for the multiplexed-engineered, off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapy, FT-522, as a potential therapeutic against autoimmune diseases.
Lift Biosciences Ltd. has been awarded a grant of over £1 million (US$1.3 million) from Innovate UK that will fund a collaboration between Lift and researchers at the University of Cambridge.
Killer immunoglobulin-like receptor (KIR)-chimeric antigen receptor (CAR) T-cell therapies have previously demonstrated superior performance and functional persistence in solid tumor models, and the mesothelin-specific KIR-CAR T cells, Synkir-110, are now being evaluated in phase I trials by Verismo Therapeutics Inc.
RSS
